How to Implement this Assessment in the Clinical Prac5ce?
|
|
|
- Judith Tucker
- 6 years ago
- Views:
Transcription
1 5th Interna*onal Symposium on Neuropsychiatry HIV Barcelona, May 24-25th, 2012 Neuropsychological Screening in HIV Infec6on: How to Implement this Assessment in the Clinical Prac5ce? Jose A. Muñoz- Moreno Lluita contra la SIDA Founda:on Germans Trias i Pujol University Hospital Barcelona, Catalonia, Spain
2 Cogni5ve Disorders in HIV Infec*on
3 Cogni5ve Disorders in HIV Infec*on HIV Specialization / Infectious Diseases
4 Cogni5ve Disorders in HIV Infec*on Health Psychology
5 Cogni5ve Disorders in HIV Infec*on Psychiatry
6 Cogni5ve Disorders in HIV Infec*on Neuropsychology
7 Cogni5ve Disorders in HIV Infec*on HIV Specialization / Neuropsychology Infectious Diseases Psychiatry Health Psychology
8 But... is the rou*ne prac*ce in accordance with these new needs in HIV Infec*on and its management??
9 Clinical Prac5ce in HIV Infec*on F HIV Physicians F Nurses F Health psychologists F Psychiatrists F Neuropsychologists!
10 Why to Assess? Which Tools? Which Pa5ents and When Monitoring?
11 Why to Assess?
12 Main Reasons þ High incidence and prevalence þ Multiple risk factors associated þ Negative contributions þ Lack of treatment þ Complexity in clinical management!
13 Prevalence of HIV- Associated NCI
14 Prevalence of HIV- Associated NCI
15 Confirming Data NEUROCOGNITIVE IMPAIRMENT * 100 Percent Impaired Australia (Cysique, 2004) Italy (Tozzi, 2005) USA - CHARTER (Heaton, 2009) Germany (Arendt, 2010) Catalonia - Spain (Muñoz- Moreno, 2010) 0 CDC- A CDC- B CDC- C Muñoz- Moreno et al, 10th Interna*onal Symposium on Neurovirology, Milan, 2010
16 Leading to Nega5ve Consequences... G Worse Quality of Life G Interference on Daily Living Ac:vi:es G Worse Adherence to An:retroviral Treatment G More Frequent Virological Failure G Predictor of Higher Death Rates Tozzi et al, 2003 Parsons et al, 2006 Schifi]o et al, 2001 Heaton et al, 2004 Gorman et al, 2009 Hinkin et al, 2004 Applebaum et al, 2009 Woods et al, 2009 Tozzi et al, 2005 Letendre et al, 2010 Ellis et al, 1997 Sevigny et al, 2007 Lescure et al, 2011
17 Interven5ons NEUROACTIVE ARV DRUGS NON- NEUROACTIVE ARV DRUGS Letendre et al, Enhancing ART for HIV Cogn*ve Disorders, Ann Neurol, 2004 Giancola et al, Neuroac*ve ART Drugs Do Not Influence NC Performance, JAIDS, 2006
18 Insufficient Although Growing Evidence An*nori, 4 th Mee*ng on HIV and CNS, Rome, 2011
19 Insufficient Although Growing Evidence An*nori, 4 th Mee*ng on HIV and CNS, Rome, 2011
20 Other ARV- Related Approaches Muñoz- Moreno et al, AIDS Res Hum Retroviruses, 2008 Ellis et al, AIDS, 2011
21 Other ARV- Related Approaches Muñoz- Moreno et al, AIDS Res Hum Retroviruses, 2008 Ellis et al, AIDS, 2011
22 Other ARV- Related Approaches Muñoz- Moreno et al, J Neurovirol, 2010
23 ARV Treatment Guidelines! Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (DHHS). December 2009: AdultandAdolescentGL.pdf
24 ARV Treatment Guidelines! Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents (DHHS), March 2012: AdultandAdolescentGL.pdf
25 Therapeu5cal Approach
26 Therapeu5cal Approach
27 Therapeu5cal Approach
28 Which Tools?
29 Comprehensive Ba[eries of Neuropsychological Tests Muñoz- Moreno JA, in Research Focus on Cogni5ve Disorders, NY, 2007
30 Why Neuropsychological Tes5ng? PROS: - Strongly recommended - Large experience in clinical neuropsychology - Experience in HIV infection - Different areas potentially assessed - Variable tools CONS: - Availability / feasibility - Duration of evaluations
31 Interna5onal Recommenda5ons F National Institute of Mental Health, 1990 F American Tasks Force, 1991 F UNAIDS, 1997 F Antinori, 2007 F Significant number of reviews and studies recommending
32 Why Neuropsychological Tes5ng? PROS: - Strongly recommended - Large experience in clinical neuropsychology - Experience in HIV infection - Different areas potentially assessed - Variable tools CONS: - Availability / feasibility - Duration of evaluations
33 Clinical Neuropsychology In multiple diseases regardless of HIV infection! Pattern of neurocognitive alteration in...: Multiple Sclerosis Schizophrenia Aging Alzheimer's Disease Parkinson's Disease ETC, ETC...
34 Neuropsychological Tes5ng PROS: - Strongly recommended - Large experience in clinical neuropsychology - Experience in HIV infection - Different areas potentially assessed - Variable tools CONS: - Availability / feasibility - Duration of evaluations
35 HIV Infec5on - Literature 2010: Neurocognitive + HIV: 357 studies / 75 reviews Neuropsychological + HIV: 1014 studies / 129 reviews Cognitive + HIV: 1934 studies / 357 reviews 2011: Neurocognitive + HIV: 470 studies / 95 reviews Neuropsychological + HIV: 1090 studies / 134 reviews Cognitive + HIV: 2095 studies / 371 reviews 2012: Neurocognitive + HIV: 594 studies / 122 reviews Neuropsychological + HIV: 1165 studies / 140 reviews Cognitive + HIV: 2265 studies / 393 reviews
36 HIV Infec5on - Literature 2010: Neurocognitive + HIV: 357 studies / 75 reviews Neuropsychological + HIV: 1014 studies / 129 reviews Cognitive + HIV: 1934 studies / 357 reviews 237! - 151! - 331! 2011: Neurocognitive + HIV: 470 studies / 95 reviews Neuropsychological + HIV: 1090 studies / 134 reviews Cognitive + HIV: 2095 studies / 371 reviews 2012: Neurocognitive + HIV: 594 studies / 122 reviews 124! - 75! - 170! Neuropsychological + HIV: 1165 studies / 140 reviews Cognitive + HIV: 2265 studies / 393 reviews
37 Neuropsychological Tes5ng PROS: - Strongly recommended - Large experience in clinical neuropsychology - Experience in HIV infection - Different areas potentially assessed - Variable tools CONS: - Availability / feasibility - Duration of evaluations
38 HIV- Associated Cogni5ve Profile - Fronto-subcortical pattern, with altered areas well defined: Attention / Working Memory Executive Functioning Information Processing Speed Verbal Fluency Learning Motor Function Verbal Memory - Maybe has this changed?? Cortical hypothesis: Brew, 2004 Valcour, 2006
39 Neuropsychological Tes5ng PROS: - Strongly recommended - Large experience in clinical neuropsychology - Experience in HIV infection - Different areas potentially assessed - Variable tools CONS: - Availability / feasibility - Duration of evaluations
40 Neurocogni5ve Areas and Tests PROCESSING INFORMATION SPEED: MOTOR FUNCTION: VERBAL MEMORY: LEARNING: EXECUTIVE FUNCTIONS: - TMT- A: Trail Making Test - Part A - GPT: Grooved Pegboard Test - CVLT- II: California Verbal Learning Test - II - TMT- B: Trail Making Test - Part B - WCST: Wisconsin Card Sor6ng Test - Stroop's Test
41 Motor Func5on Grooved Pegboard Test Ma[hews, 1964
42 Verbal Memory and Learning California Verbal Learning Test - II Delis, 2000
43 Execu5ve Func5oning Wisconsin Card Sor:ng Test (WCST) Kongs, 1993
44 Informa5on Processing Speed Trail Making Test - Part A (TMT- A) SORTIDA FI Reitan, 1974
45 Execu5ve Func5oning Trail Making Test - Part B (TMT- B) Reitan, 1974
46 Execu5ve Func5oning Stroop's Test Golden, 1978
47 Comprehensive Assessment - Recommendations by Frascati Group, in Antinori et al, Neurology, 2007: Table 1. Criteria for clinical diagnosis of central nervous system disorders in HIV-infected adults and adolescents Table 2. HAND criteria Table 3. Examples of tests Table 4. Guidelines for classifying confounds to HIV-associated neurocognitive disorders
48 Confounding Factors "Evidence of another etiology, including active CNS opportunistic infection or malignancy, psychiatric disorders (e.g., depressive disorder), active alcohol or substance use, or acute or chronic substance withdrawal, must be sought from history, physical and psychiatric examination, and appropriate laboratory and radiologic investigation (e.g., lumbar puncture, neuroimaging). If another potential etiology (e.g., major depression) is present, it is not the cause of the above cognitive, motor, or behavioral symptoms and signs." Mainly: - Drug abuse - CNS opportunistic infections - Psychatric or emotional disorders
49 Depression and Anxiety Symptoms - Hospital Anxiety and Depression Scale (HADS): Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: Beck Depression Inventory (BDI): Beck AT, Rush AJ, Shaw BF, and Emery G: Cognitive Therapy of Depression. Guilford Press, New York, State-Trait Anxiety Inventory (STAI): Spielberger CD, Gorsuch RL, and Lushene RE: Manual for the State- Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA, 1970.
50 Depression Symptoms Hospital Anxiety and Depression Scale (HADS) - 14 items - 2 scales - 1 total scale Golden, 1978
51 Depression Symptoms Beck Depression Inventory (BDI) - 21 items - 1 scale - 2 sub-scales Golden, 1978
52 Anxiety Symptoms State- Trait Anxiety Inventory (STAI) - 20 items - 1 scale Golden, 1978
53 Limita5ons in HIV Clinical Prac5ce PROS: - Strongly recommended - Large experience in clinical neuropsychology - Experience in HIV infection - Different areas potentially assessed - Variable tools CONS: - Availability / feasibility - Duration of evaluations
54 Availability and Applicability MAIN LIMITATIONS: - Need of a trained neuropsychologist - Expertise and skills are relevant aspects in the application - Multiple tools - Manipulative tools, as well as variable instructions and correction processes - Duration of assessments! (next section)
55 Limita5ons in HIV Clinical Prac5ce PROS: - Strongly recommended - Large experience in clinical neuropsychology - Experience in HIV infection - Different areas potentially assessed - Variable tools CONS: - Availability / feasibility - Duration of evaluations
56 Time Required for Neuropsychological Tes5ng - NIMH, 1990: 2 recommendations Extended: 7-9 hours of duration Brief: 1-2 hours of duration - Nowadays... Extended: 2-3 hours of duration Brief:?????
57 Time Required for Neuropsychological Tes5ng - NIMH, 1990: 2 recommendations Extended: 7-9 hours of duration F Relevance of using Screening Tools! Brief: 1-2 hours of duration - Nowadays... Extended: 2-3 hours of duration
58 What Do We Know About Screening Tools?
59 What Do We Know About Screening Tools?
60 What Do We Know About Screening Tools?
61 What Do We Know About Screening Tools?
62 What Do We Know About Screening Tools?
63 What Do We Know About Screening Tools?
64 What Do We Know About Screening Tools?
65 What Do We Know About Screening Tools?
66 Which Pa6ents? Which Pa5ents and When Monitoring?
67 Characteris5cs of Pa5ents: Which Predictors? According to biomarkers? According to clinical factors? According to demographic variables? According to emotional variables? According to subjective complaints?
68 Clinical Factors F High number of clinical factors are associated Some of most representative: F AIDS F CD4 Nadir F Time with HIV F Interruptions of ART F Coinfection with HCV F Virological Failure (in Plasma) F CSF Viral Load * *: Considering availability of lumbar puncture in clinical practice!
69 Demographic Factors Well identified: F Older Age F Education Level (Cognitive Reserve!) F Employment!
70 Self- Reported NC Complaints Muñoz-Moreno et al, INS, Helsinki, 2009
71 Self- Reported NC Complaints 3 patients' patterns according to presence or not of NC complaints: F 1) NC Complaint + Neurocognitive Impairment F 2) NC Complaint + No Neurocognitive Impairment F 3) No NC Complaint + Neurocognitive Impairment!
72 And When Monitoring?
73 Similar Findings Muñoz-Moreno et al, CROI, 2010
74 Clinical Factors As Predictors - Current CD4 cell count ( <123 cells/µl) - Time with HIV ( >2.7 years) *: 75.8% of correct classifica*on
75 Clinical Factors As Predictors - Nadir CD4 cell count ( <365 cells/µl) - Time on current regimen ( >32.2 months) - Highest viral load ( >4.5 cop/ml) *: 88.4% and 84.9% of correct classifica*on
76 Monitoring: 6 months Impairment not associated with HIV Pa5ent Approach based on: - NC Complaint - Interference in Func6oning Screening - PAOFI - IADLs - Self- reported Neurocogni5ve Tes5ng Screening Method Impairment associated with HIV: ANI No impairment Impairment No impairment Interven:on
77 Clinician Approach based on clinical suspicion according to: - Clinical Risk Factors, par:cularly: Interference / Complaints: MND Monitoring: 6 months AIDS CD4 Nadir Time with HIV Interrup6ons of ART Coinfec6on with HCV Virological Failure Neurocogni5ve Tes5ng Impairment No Impairment NO Interference / Complaints: ANI Interven:on *In case of Lumbar Puncture availability: Screening Method CSF Viral Load* - Addi:onal Risk Factors: Aging Educa6on Others Impairment No impairment
78
79 Thanks for your a[en5on! Jose A. Muñoz- Moreno
International Symposium on. Barcelona, May 5 th and 6 th 2011
th International Symposium on Barcelona, May 5 th and 6 th 2011 4rd Symposium on Psychiatry and HIV --- Barcelona, May 6th 2010 Neurocognitive Testing in HIV Infection: How to Implement this Assessment
HIV and Brain Func.on. Tristan J Barber Research Physician St Stephen s AIDS Trust Chelsea and Westminster Hospital
HIV and Brain Func.on Tristan J Barber Research Physician St Stephen s AIDS Trust Chelsea and Westminster Hospital HIV and the Brain When can HIV affect the brain? Seroconversion Long term infected (not
HIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV
The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV Arianna Perra, P syd, Moira Dux, PhD Terry Lee- Wilk, PhD HIV and HCV in the VA VA is the largest provider
Measurement and Classification of Neurocognitive Disability in HIV/AIDS Robert K. Heaton Ph.D University of California San Diego Ancient History
Measurement and Classification of Neurocognitive Disability in HIV/AIDS Robert K. Heaton Ph.D University of California San Diego Ancient History Group Means for NP and MMPI Variables N=381 Consecutive
Central Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
HAND is Common and Important in Patients on ART
HAND is Common and Important in Patients on ART Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego How is HAND diagnosed? How prevalent is it? Points
Issues of Neuropsychological Assessment in International Settings
Issues of Neuropsychological Assessment in International Settings Kevin Robertson, Ph.D. Director of Neuropsychology, Neurology University of North Carolina at Chapel Hill Igor Grant, M.D. Director, HIV
International Forum on HIV and Rehabilitation Research
Neurocognitive screening and behavioural interventions for HIV-Associated Neurocognitive Disorders (HAND) International Forum on HIV and Rehabilitation Research Translating Research Evidence from the Canada-UK
Differential diagnosis between depression and neurocognitive impairment in HIV-infected persons
Differential diagnosis between depression and neurocognitive impairment in HIV-infected persons Dr. Adriana Carvalhal, MD, MSc, PhD University of Toronto - Canada Disclosure Research: Canadian Institute
Detecting neurocognitive impairment in HIV-infected youth: Are we focusing on the wrong factors?
Detecting neurocognitive impairment in HIV-infected youth: Are we focusing on the wrong factors? Jennifer Lewis, PsyD; Mathew Hirsch, PsyD & Susan Abramowitz, PhD NYU School of Medicine, New York, NY Friday,
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
HIV & Women: Neurological Issues
HIV & Women: Neurological Issues Scott Letendre, M.D. Professor of Medicine University of California, San Diego 1 Do women differ from men in their risk for neurocognitive and mood disorders? 2 As the
DSM-5 and HAND. Diagnosis and Monitoring of HAND 10/6/2015. APA Institute on Psychiatric Services New York City
Diagnosis and Monitoring of HAND Karl Goodkin, MD, PhD Professor and Chair Department of Psychiatry and Behavioral Sciences East Tennessee State University Norman C. Moore, MD Director of Research, Professor
COGNITIVE DYSFUNCTION AMONG HIV-POSITIVE PATIENTS ATTENDING CCC AT KENYATTA NATIONAL HOSPITAL
COGNITIVE DYSFUNCTION AMONG HIV-POSITIVE PATIENTS ATTENDING CCC AT KENYATTA NATIONAL HOSPITAL Principal Investigator Dr. Zaheer Bagha Supervisors Prof. E. Amayo Prof. A. M. Adam Dr. J. O. Mecha INTRODUCTION
Management of a HIV-infected patient with a psychiatric disorder
Management of a HIV-infected patient with a psychiatric disorder Maria Ferrara, Modena, Italia Guida Da Ponte, Lisboa, Portugal Jordi Blanch, Barcelona Main complaint Mr M is a 30-year-old HIV+ man In
Approach to HIV Associated Neurocognitive disorders (HAND)
Approach to HIV Associated Neurocognitive disorders (HAND) Dinesh Singh MB ChB (Natal), M Med (Psych) (Natal), F CPsych (SA), MS (epi) (Columbia, USA), PhD (candidate UKZN) 2 October 2009 ICC, Durban Overview
Psychiatric Symptom Burden in Elders with HIV-Associated Neurocognitive Disorders
Psychiatric Symptom Burden in Elders with HIV-Associated Neurocognitive Disorders Benedetta Milanini 1, Stephanie Catella 2, Lauren Wendelken 2, Pardis Esmaeili 2, Hannah Jang 2, Robin Ketelle 2, Victor
HIV Neurology Persistence of Cognitive Impairment Despite cart
HIV Neurology Persistence of Cognitive Impairment Despite cart Victor Valcour MD PhD Professor of Medicine Memory and Aging Center, Dept. of Neurology University of California San Francisco, USA 8 th International
HIV Associated Neurocognitive Disorders in the era of modern CART
HIV Associated Neurocognitive Disorders in the era of modern CART Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego Points to be covered HIV associated
Neuropsychological assessment in HIV/AIDS and its challenges in Galati County
Neuropsychological assessment in HIV/AIDS and its challenges in Galati County Manuela Arbune Dunarea de Jos U i e sit Galati București, October 5-6, 2015 Background HAND persists despite ARV (~50%). Neu
Neuropsychological Evaluation of
Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish
Dr Ria Daly. Birmingham Heartlands Hospital. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Ria Daly Birmingham Heartlands Hospital 18-20 April 2012, The International Convention Centre, Birmingham 18 th Annual Conference of the
The prevalence of HIV-associated neurocognitive
The authors investigated the combined age and HIV effects on cognitive functions in 146 individuals, 116 of whom had HIV infection. Fortytwo percent had HIV-associated neurocognitive disorder, and all
Antiviral Therapy 2013; 18: (doi: /IMP2560)
Antiviral Therapy 2013; 18:153 160 (doi: 10.3851/IMP2560) Original article Revised central nervous system neuropenetrationeffectiveness score is associated with cognitive disorders in HIV-infected patients
CAB 59: HIV and neurocogni5ve impairment
HIV Neurology CAB 59: HIV and neurocogni5ve impairment Friday 8 th July 2016 Dr Nick Davies Consultant Neurologist, Chelsea & Westminster Hospital & Imperial College NHS Trust (Charing Cross Hospital),
Clinical notes: Management of HAART in patients with HAND
Clinical notes: Management of HAART in patients with HAND Paola Cinque Dipartment of Infectious Diseases San Raffaele Scientific Institute, Milano, Italy 11 Residential Course on Clinical Pharmacology
Good Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection
BRIEF REPORT: CLINICAL SCIENCE Good Neurocognitive Performance Measured by the International HIV Dementia Scale in Early HIV-1 Infection Gustavo D. Lopardo, MD,* Emiliano Bissio, MD,* María del C. Iannella,*
The Relationship Between Age and Cognitive Function in HIV-Infected Men
The Relationship Between Age and Cognitive Function in HIV-Infected en Emily C. Kissel Nicole D. Pukay-artin, B.A. Robert A. Bornstein, Ph.D. Several studies have identified increased age as a risk factor
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
AIDS 2011, 3, 2011 RW
Treating CNS HIV Infection and Disease Why, How and When? Richard W. Price, M.D. Department of Neurology, UCSF/SFGH Preface: Reasons for Renewed Interest in Treatment of CNS HIV Continued CNS infection/disease
High rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents
High rates of asymptomatic neurocognitive impairment are observed in perinatally HIV-infected adolescents YasotharanParamesparan, Jane Ashby, Lucy Garvey, Caroline Foster, Sarah Fidler, Alan Winston Background
Emerging Considerations in neuroaids Internationally: Events in Acute and Early Infection
Emerging Considerations in neuroaids Internationally: Events in Acute and Early Infection Igor Grant, M.D. Director, HIV Neurobehavioral Research Center University of California, San Diego Although combination
Neurocognitive Impairments in HIV: Natural History, Impacts on Everyday Functioning and Promising Interventions
Neurocognitive Impairments in HIV: Natural History, Impacts on Everyday Functioning and Promising Interventions Sean B. Rourke, Ph.D. Scientist and Neuropsychologist, St. Michael s Hospital Director, CIHR
Caring for HIV infected patients in Spain during the current economical crisis
Caring for HIV infected patients in Spain during the current economical crisis Bonaventura Clotet. HIV Unit Univ Hosp Germans Trias i Pujol Badalona, Barcelona, Catalonia Spain CRISIS? WHAT CRISIS? Rationale.
Cognitive impairment among Indonesia HIV naïve patients
Neurology Asia 2015; 20(2) : 155 160 Cognitive impairment among Indonesia HIV naïve patients 1 Riwanti Estiasari MD, 1 Darma Imran MD, 1 Diatri Nari Lastri MD, 1 Pukovisa Prawirohardjo MD, 1,2 Patricia
natural history of the disease, there is no rationale for limiting screening of cognitive
Assessment, Diagnosis and Treatment of Human Immunodeficiency Virus (HIV)- associated Neurocognitive Disorders (HAND): AConsensus Report of the Mind Exchange Program Supplementary Materials Full practical
Lambros Messinis PhD. Neuropsychology Section, Department of Neurology, University of Patras Medical School
Lambros Messinis PhD Neuropsychology Section, Department of Neurology, University of Patras Medical School Type 2 Diabetes Mellitus is a modern day epidemic Age is a significant predictor of diabetes Males
Neuropsychological Testing (NPT)
Neuropsychological Testing (NPT) POLICY Psychological testing (96101-03) refers to a series of tests used to evaluate and treat an individual with emotional, psychiatric, neuropsychiatric, personality
The Brief Cogni-ve Assessment Tool (BCAT): A New Test Emphasizing Contextual Memory and Execu<ve Func<ons
The Brief Cogni-ve Assessment Tool (BCAT): A New Test Emphasizing Contextual Memory and Execu
CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE
CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there
Characterizing HIV-Associated Neurocognitive Disorder in Two Underserved Sociodemographic Groups
University of Miami Scholarly Repository Open Access Dissertations Electronic Theses and Dissertations 2015-03-31 Characterizing HIV-Associated Neurocognitive Disorder in Two Underserved Sociodemographic
Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives
SUPPLEMENTARY MATERIAL Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives B. Arts 1 *, N. Jabben 1, L. Krabbendam 1 and J. van Os 1,2 1 Department of Psychiatry
Diagnosis and Monitoring of HAND
Diagnosis and Monitoring of HAND Norman C. Moore, MD Professor, Director of Research Department of Psychiatry and Behavioral Sciences Quillen College of Medicine APA 2015 Disclosure: Karl Goodkin, MD,
CALIFORNIA STATE UNIVERSITY, NORTHRIDGE APATHY AND DEPRESSION AS PREDICTORS OF NEUROCOGNITVE
CALIFORNIA STATE UNIVERSITY, NORTHRIDGE APATHY AND DEPRESSION AS PREDICTORS OF NEUROCOGNITVE PERFORMANCE AND PSYCHOSOCIAL FUNCTIONING IN AN HIV-POSITIVE POPULATION A thesis submitted in partial fulfillment
Low a&ainment of virologic suppression among HIV- infected children on an;retroviral treatment 12 months a>er virologic failure in western Kenya
Low a&ainment of virologic suppression among HIV- infected children on an;retroviral treatment 12 months a>er virologic failure in western Kenya University of Nairobi of Nairobi Annual HIV/AIDS Collabora;ve
HIV-1 Dual Infection and Neurocognitive Impairment
HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral
The Impact of HIV and Aging on the Brain Scott Letendre, M.D.
The Impact of HIV and Aging on the Brain Scott Letendre, M.D. Professor of Medicine and Psychiatry University of California, San Diego Disclosures Research funds were paid to UC San Diego on behalf of
Antiviral Therapy 2015; 20: (doi: /IMP2926)
Antiviral Therapy 2015; 20:441 447 (doi: 10.3851/IMP2926) Original article Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for
Perspec'vas Psicologicas en el Cuidado de la Diabetes
Perspec'vas Psicologicas en el Cuidado de la Diabetes Antonio E. Puente University of North Carolina Wilmington Universidad de la Ciudad de Juarez 09.20.13 Health Sta's'cs: 2010 (The Economist, 12.12.09)
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline Igor Grant, MD Donald R. Franklin, Jr., BS Reena Deutsch, PhD Steven P. Woods, PsyD Florin Vaida, PhD Ronald
Carmen Inoa Vazquez, Ph.D., ABPP Clinical Professor NYU School of Medicine Lead Litigation Conference Philadelphia May 19, 2009 Presentation
Carmen Inoa Vazquez, Ph.D., ABPP Clinical Professor NYU School of Medicine Lead Litigation Conference Philadelphia May 19, 2009 Presentation Neuropsychological Tests Battery The following List represents
HIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
HIV-Associated Neurocognitive Disorders (HAND) Aroonsiri Sangarlangkarn, MD, MPH, Jonathan S. Appelbaum, MD, FACP
HIV-Associated Neurocognitive Disorders (HAND) Aroonsiri Sangarlangkarn, MD, MPH, Jonathan S. Appelbaum, MD, FACP Educational Objectives By the end of the session, learners will be able to: 1. Describe
Effects of severe depression on TOMM performance among disability-seeking outpatients
Archives of Clinical Neuropsychology 21 (2006) 161 165 Effects of severe depression on TOMM performance among disability-seeking outpatients Y. Tami Yanez, William Fremouw, Jennifer Tennant, Julia Strunk,
COGNITIVE FUNCTIONING IN ADULTS AGING WITH HIV: EXPLORING COGNITIVE SUBTYPES AND INFLUENTIAL FACTORS PARIYA L. FAZELI
COGNITIVE FUNCTIONING IN ADULTS AGING WITH HIV: EXPLORING COGNITIVE SUBTYPES AND INFLUENTIAL FACTORS by PARIYA L. FAZELI DAVID E. VANCE, COMMITTEE CO-CHAIR KARLENE K. BALL, COMMITTEE CO-CHAIR VIRGINIA
HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project
DOI: 10.1111/hiv.12137 ORIGINAL RESEARCH HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project NS Ku, 1 Y Lee, 2 JY Ahn, 1 JE Song, 1 MH Kim, 1 SB Kim, 1 SJ Jeong,
Plenary Session 2 Psychometric Assessment. Ralph H B Benedict, PhD, ABPP-CN Professor of Neurology and Psychiatry SUNY Buffalo
Plenary Session 2 Psychometric Assessment Ralph H B Benedict, PhD, ABPP-CN Professor of Neurology and Psychiatry SUNY Buffalo Reliability Validity Group Discrimination, Sensitivity Validity Association
Forget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?)
Forget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?) Dr Simon Rackstraw FRCP Medical Director, Mildmay Hospital, London Consultant
Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors
(2000) 6, 84 ± 88 ã 2000, Inc. www.jneurovirol.com Short Communication Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors Ned Charlton Sacktor*,1, Richard
Sandra Weintraub, PhD Clinical Core Leader and Professor
Sandra Weintraub, PhD Clinical Core Leader and Professor Northwestern Cognitive Neurology and Alzheimer s Disease Center (CNADC) Chicago, Illinois www.brain.northwestern.edu Why is it so difficult to diagnose
Switching strategies and ARV treatment costs
February 2014 Switching strategies and ARV treatment costs Josep M Llibre/Bonaventura Clotet Fundació Lluita contra la SIDA Hosp Univ Germans Trias i Pujol Badalona Rationale. Spain is under a huge economic
Hospital Anxiety and Depression Scale (HAD): some psychometric data for a Swedish sample
Acta Psychiatr Scand 1997: 96: 281-286 Printed in UK - all rights reserved Hospital Anxiety and Depression Scale (HAD): some psychometric data for a Swedish sample Copyright 0 Munksgaard I997 ACTA PSYCH
Safety of Current Antiretroviral Therapy on the CNS Scott Letendre, M.D.
Safety of Current Antiretroviral Therapy on the CNS Scott Letendre, M.D. Professor of Medicine and Psychiatry University of California, San Diego Disclosures Research funds were paid to UC San Diego on
Definitional Criteria Working Group 1: Toward an Updated Nosology for HIVassociated Neurocognitive Disorders
Definitional Criteria Working Group 1: Toward an Updated Nosology for HIVassociated Neurocognitive Disorders Prepared by Igor Grant for Working Group 1 consisting of: Desiree Byrd, Mariana Cherner, David
Valutazione dei disturbi neurocognitivi e invecchiamento: non solo HAND. Workshop Nazionale CISAI Lecco 20 Marzo 2015
Valutazione dei disturbi neurocognitivi e invecchiamento: non solo HAND Workshop Nazionale CISAI Lecco 20 Marzo 2015 Paola Cinque Dipartimento di Malattie Infettive Istituto Scientifico San Raffaele, Milano
Improvement of Quality of Life after the Application of Mindfulness-Based Cognitive Therapy in Subjects Aging with HIV Infection
Improvement of Quality of Life after the Application of Mindfulness-Based Cognitive Therapy in Subjects Aging with HIV Infection Carmina R. Fumaz HIV Unit-LLuita contra la Sida Foundation Germans Trias
Neurocogni*ve tes*ng and cochlear implanta*on: insights into performance in older adults
Neurocogni*ve tes*ng and cochlear implanta*on: insights into performance in older adults Maura K Cosetti 1 MD James B. Pinkston, PhD 1 ; Jose M. Flores, MPH, PhD 3 ; David R. Friedmann, MD 2 ; Callie B.
M P---- Ph.D. Clinical Psychologist / Neuropsychologist
M------- P---- Ph.D. Clinical Psychologist / Neuropsychologist NEUROPSYCHOLOGICAL EVALUATION Name: Date of Birth: Date of Evaluation: 05-28-2015 Tests Administered: Wechsler Adult Intelligence Scale Fourth
Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons
Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons Nancy F. Crum-Cianflone, David J. Moore, Scott Letendre, et al. Neurology 2013;80;371; Published online before
HAND Diagnostic Issues Addressing Mental Health. Dr. Adriana Carvalhal, MD, MSc, PhD University of Toronto St. Michael s Hospital
HAND Diagnostic Issues Addressing Mental Health Dr. Adriana Carvalhal, MD, MSc, PhD University of Toronto St. Michael s Hospital Disclosure Research: Canadian Institute Health Research (CIHR) - I Ontario
Summary of ARV prescribing guidelines in London
Summary of ARV prescribing guidelines in London These slides summarise the recommenda1ons by the London HIV Consor1um for prescribing an1retrovirals. April 2011 HIV posi1ve people should discuss these
Disclosures 12/7/17. UPDATES IN HIV NEUROLOGY Felicia Chow, MD, MAS University of California, San Francisco December 7, 2017
UPDATES IN HIV NEUROLOGY Felicia Chow, MD, MAS University of California, San Francisco December 7, 2017 Disclosures I have nothing to disclose. Brain Compartment Zayyad et al. Curr HIV/AIDS Rep 2015 Clinical
Nature, prevalence and clinical significance. Barcelona, Spain
Nature, prevalence and clinical significance Jaime Kulisevsky Barcelona, Spain 1 Non motor (neuropsychiatric) symptoms are an integral part of Parkinson s s disease (PD) Affective disorders And are associated
Recrea&onal Therapy. Thomas K. Skalko, Ph.D., LRT/CTRS Chair, Commi<ee on Accredita&on of Recrea&onal Therapy Educa&on
Recrea&onal Therapy Thomas K. Skalko, Ph.D., LRT/CTRS Chair, Commi
Ronette Goodwin, Ph.D. Forensic and Psychological Experts, Inc Crenshaw Blvd. #179 Torrance, CA (866)
Ronette Goodwin, Ph.D. Forensic and Psychological Experts, Inc. 2390 Crenshaw Blvd. #179 Torrance, CA. 90501 (866) 853-0056 goodwindoc@aol.com ACADEMIC BACKGROUND August 2001 Harbor UCLA Medical Center,
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection
Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection Teresa H. Evering a, Allison Applebaum b, Melissa La Mar a,
Learning objectives 6/20/2018
Cognitive impairment of patients with chronic migraine, in a neuropsychological assessment, does not depend on the use of topiramate or comorbidities Ferreira KS, MD, PhD Professor, Neurology Clinic, Medicine
Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention
The Alfred Hospital Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Final Report August 2005 Chief Investigator Associate Professor Anne Mijch Infectious Diseases
Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?
Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? Matteo Vassallo a,b, Jacques Durant a, Virginie Biscay a, Christine
Erica Weber, Kaitlin Blackstone & Steven Paul Woods
Cognitive Neurorehabilitation of HIVassociated Neurocognitive Disorders: A Qualitative Review and Call to Action Erica Weber, Kaitlin Blackstone & Steven Paul Woods Neuropsychology Review ISSN 1040-7308
January 18 th, 2018 Brixen, Italy
From Subjective Cognitive Decline to Alzheimer s Disease: the predictive role of neuropsychological, personality and cognitive reserve features. A 7-years Follow-Up study. S. Mazzeo *, V. Bessi *, S. Padiglioni
The exploration of neuropsychological disorders in HAART- naïve young adults in South Africa
1 The exploration of neuropsychological disorders in HAART- naïve young adults in South Africa Nomakhawuta Moshani ACSENT Laboratory Department of Psychology University of Cape Town Supervisors: Dr Kevin
Supplementary Online Content
Supplementary Online Content Sun LS, Li G, Miller TLK, et al. Association between a single general anesthesia exposure before age 36 months and neurocognitive outcomes in later childhood. JAMA. doi:10.1001/jama.2016.6967
Mild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
The Role of Cardiovascular Risk and Aging in Memory Performance in a Sample of Veterans with HIV
The Role of Cardiovascular Risk and Aging in Memory Performance in a Sample of Veterans with HIV LYNN KAKOS, PH.D. VA MARYLAND HEALTH CARE SYSTEM (VAMHCS) OBJECTIVES HIV in the VA Neurocognitive profile
Progress in understanding the pathogenesis of HIV-1-
The authors previously found a strong association between elevated HIV proviral DNA (HIV DNA) and a diagnosis of HIV-1-associated dementia (HAD) vs. normal cognition. It is unclear whether HIV DNA globally
Correspondence should be addressed to Torun Gangaune Finnanger; Received 25 June 2015; Accepted 1 September 2015
Behavioural Neurology Volume 2015, Article ID 329241, 19 pages http://dx.doi.org/10.1155/2015/329241 Research Article Life after Adolescent and Adult Moderate and Severe Traumatic Brain Injury: Self-Reported
Risky Decision Making Assessed With the Gambling Task in Adults with HIV
Digital Commons@ Loyola Marymount University and Loyola Law School Psychology Faculty Works Psychology 5-1-2006 Risky Decision Making Assessed With the Gambling Task in Adults with HIV David J. Hardy Loyola
21/05/2018. Today s webinar will answer. Presented by: Valorie O Keefe Consultant Psychologist
Today s webinar will answer. 1. What is the RBANS, and how is the updated version different than the original version? 2. What are the neurocognitive areas assessed by the RBANS and what scores are available?
When to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
While great progress has been made in understanding
Human immunodeficiency virus (HIV) DNA in peripheral blood mononuclear cells was previously associated with neuropsychological function. By including individuals encompassing the full range of HIV-1-associated
DOI: /hiv British HIV Association HIV Medicine (2013), 14, SHORT COMMUNICATION
DOI: 10.1111/hiv.12008 SHORT COMMUNICATION Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless
DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
DOES IMPAIRED EXECUTIVE FUNCTIONING DIFFERENTIALLY IMPACT VERBAL MEMORY MEASURES IN OLDER ADULTS WITH SUSPECTED DEMENTIA?
The Clinical Neuropsychologist, 20: 230 242, 2006 Copyright # Taylor and Francis Group, LLC ISSN: 1385-4046 print=1744-4144 online DOI: 10.1080/13854040590947461 DOES IMPAIRED EXECUTIVE FUNCTIONING DIFFERENTIALLY
Since the introduction of highly-active antiretroviral
Family History of Dementia Predicts Worse Neuropsychological Functioning Among HIV-Infected Persons David J. Moore, Ph.D. Miguel Arce, B.A. Suzanne Moseley, B.S. J. Allen McCutchan, M.D. Jennifer Marquie-Beck,
Medikal Fizik Çalışmaları
Medikal Fizik Çalışmaları Zeynep Özen Acıbadem Altunizade Hastanesi Major Themes Treatment Planning and Delivery (in SRS/SBRT) Improving Quality and Consistency in Clinical Trials via Knowledge- Based
Analysis of Gender Differences in Self-Statements and Mood Disorders
Suggested APA style reference information can be found at http://www.counseling.org/knowledge-center/vistas Article 41 Analysis of Gender Differences in Self-Statements and Mood Disorders Robert DeVore
Note: These are abbreviated slides with graphics and other protected content removed for electronic posting purposes with NAPSA.
Note: These are abbreviated slides with graphics and other protected content removed for electronic posting purposes with NAPSA. Please attend the presentation for the full slideshow and information. Attendees